ClinicalTrials.gg
Not yet recruitingNCT07236060Updated Nov 19, 2025

Ultrasound Model to Help Differentiate Between Placenta Accreta Spectrum and Uterine Dehiscence in 3rd Trimester Pregnancies

An observational study in Placenta Accreta, Third Trimester and Uterine Scar Dehiscence, sponsored by Assiut University. Not yet recruiting. Open to female participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2025-11-19.

Sponsored by Assiut University · Observational

Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
50
Ages
18 Years to 50 Years
Sex
Female
01

Study summary

By using 2d Ultrasound on 3rd trimester pregnant women, a model is made to help differentiate between placenta accreta spectrum and uterine scar dehiscence before operative action to help prepare multi-disciplinary steps if needed

Read the detailed description

A cross-sectional observational study

02

Conditions studied

  • Placenta Accreta, Third Trimester
  • Uterine Scar Dehiscence

Browse trials for

03

In context

Placenta Accreta

150 studies on the registry are indexed under Placenta Accreta; 40 are open to participants now.

This study's planned enrollment of 50 is below the median of 87 across 78 observational studies indexed under Placenta Accreta.

Browse Placenta Accreta studies →

Lead sponsor

Assiut University is the lead sponsor of 5,078 studies on the registry; 2,178 are open to participants now.

Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Female patients admitted to women health hospital, Assiut university, Assiut

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women in 3rd trimester pregnancy with low lying placenta previa
  • History of 1 or more C-section
  • Patients planning to deliver baby in Assiut women health hospital
  • Willing and able to participate

Exclusion criteria

Exclusion Criteria:

  • Antepartum Hemorrhage(sever attack) as it hinders time for accurate diagnosis and calling expert team of diagnosis
05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
50 participants (estimated)
Patient registry
No

Interventions

  • Device2D ultrasound doppler

    using 2d ultrasound doppler to form a model that will help distinguish between placenta accreta spectrum and uterine scar dehiscence pre-operatively

06

What researchers measure

Primary outcomes

  1. Model for percise diagnosis of placenta accreta spectrum Using 2d and/or 3d ultrasound doppler to assess: Placental site

    Time frame: (gestational age 28wk-full term) till operation

  2. Model for percise diagnosis of placenta accreta spectrum Using 2d and/or 3d ultrasound doppler to assess: placental thickness

    Time frame: (gestational age 28wk- full term) till operation

  3. Model for percise diagnosis of placenta accreta spectrum Using 2d and/or 3d ultrasound doppler to assess: placental size

    Time frame: (gestational age 28wk- fullterm) till operation

  4. Model for percise diagnosis of placenta accreta spectrum Using 2d and/or 3d ultrasound doppler to assess: placental lacunae

    Time frame: (gestational age 28wk-full term) till operation

  5. Model for percise diagnosis of placenta accreta spectrum Using 2d and/or 3d ultrasound doppler to assess: Loss of placental hypoechoic zone

    Time frame: (gestattional age 28wk-full term) till operation

  6. Model for percise diagnosis of placenta accreta spectrum Using 2d and/or 3d ultrasound doppler to assess: Mean systolic velocity in both uterine arteries

    Time frame: (gestational age 28wks-full term) till time of operation

  7. Model for percise diagnosis of placenta accreta spectrum Using 2d and/or 3d ultrasound doppler to assess: Peak systolic velocity in uteroplacental interface

    Time frame: (gestational age 28wks- full term) till operation

  8. Model for percise diagnosis of placenta accreta spectrum Using 2d and/or 3d ultrasound doppler to assess: Peak systolic velocity in uterovesical interface

    Time frame: (gestational age 28wks- full term) ill operation

Secondary outcomes

  1. precise diagnosis of uterine dehiscence Using 2d and/or 3d ultrasound doppler to assess: Placental site

    Time frame: (gestational age 28wk- fullterm) till operation

  2. precise diagnosis of uterine dehiscence Using 2d and/or 3d ultrasound doppler to assess: Placental size

    Time frame: (gestational age 28wk- full term)till the operation

  3. precise diagnosis of uterine dehiscence Using 2d and/or 3d ultrasound doppler to assess: Placental thickness

    Time frame: (gestational age 28wk-full term) till operation

  4. precise diagnosis of uterine dehiscence Using 2d and/or 3d ultrasound doppler to assess: Placental lacunae

    Time frame: (gestational age 28wk- fullterm) till operation

  5. precise diagnosis of uterine dehiscence Using 2d and/or 3d ultrasound doppler to assess: Loss of placental hypoechoic zone

    Time frame: (gestational age 28wks - fullterm) till operation

  6. precise diagnosis of uterine dehiscence Using 2d and/or 3d ultrasound doppler to assess: Mean systolic velocity in both uterine arteries

    Time frame: (gestational age 28wk- fullterm) till operation

  7. precise diagnosis of uterine dehiscence Using 2d and/or 3d ultrasound doppler to assess: Peak systolic velocity in uteroplacental interface

    Time frame: (gestational age 28wk- fullterm) till operation

  8. precise diagnosis of uterine dehiscence Using 2d and/or 3d ultrasound doppler to assess: Peak systolic velocity in uterovesical interface

    Time frame: (gestational age 28wk-full term) till operation

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2025; primary completion for Nov 2026, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2025
First posted
Nov 19, 2025
StartEst.
Nov 15, 2025
Primary completionEst.
Nov 15, 2026
CompletionEst.
Dec 15, 2026
Last update
Nov 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07236060
Lead sponsor
Assiut University
Responsible party
Mostafa Ahmed Mohammed Refaat Askalany (Resident, Assiut University) — Principal investigator
First posted
Nov 19, 2025
Start date
Nov 15, 2025 (estimated)
Primary completion
Nov 15, 2026 (estimated)
Completion
Dec 15, 2026 (estimated)
Last update
Nov 19, 2025

Study contacts

Mostafa A Askalany
Contact
mostafaaskalany90@yahoo.com
+201022554284
Hassan s Kamel
Contact
kamelhs108@gmail.com
+201006664910

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion